Hormones in heart failure--regulation and counterregulation

A J Riegger1

  • 1Medizinische Universitätsklinik, Würzburg, FRG.

European Heart Journal
|August 1, 1991
PubMed

Insights

Neurohumoral mechanisms significantly impact heart failure. Early intervention targeting these systems, like atrial natriuretic peptide, can slow disease progression and improve survival in congestive heart failure patients.

Area of Science:

  • Cardiology
  • Physiology

Background:

  • Neurohumoral mechanisms are key regulators of cardiac performance in chronic heart failure, affecting myocardial function and hemodynamics.
  • Key factors include vasoconstrictors (renin-angiotensin-aldosterone system, sympathetic nerve activity, vasopressin) and vasodilators (atrial natriuretic peptide, prostaglandins, dopamine).

Purpose of the Study:

  • To explore the role of neurohumoral mechanisms in the progression of chronic heart failure.
  • To evaluate the potential of therapeutic interventions targeting these mechanisms for improved patient outcomes.

Main Methods:

  • Review of experimental and clinical studies on neurohumoral factors in heart failure.
  • Analysis of the interplay between neurohumoral systems and disease severity.

Main Results:

  • Sympathetic nerve activity and atrial natriuretic peptide increase in early heart failure.
  • Atrial natriuretic peptide initially suppresses the renin-angiotensin-aldosterone system, preserving renal function.
  • In severe heart failure, renin-angiotensin-aldosterone system activation, fluid retention, and elevated vasopressin are observed.

Conclusions:

  • Early therapeutic strategies to modulate neurohumoral activity are crucial for managing congestive heart failure.
  • Interventions supporting protective factors like atrial natriuretic peptide may delay disease progression and enhance survival.

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.8K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.7K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626